BCR-ABL Monoclonal Antibody (7C6) | Invitrogen MA1-153 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

BCR-ABL Monoclonal Antibody (7C6)

catalog :

MA1-153

quantity :

100 ug

price :

US 491.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

7C6

The same clone is also sold as:

Santa Cruz Biotechnology: sc-103

reactivity :

human, mouse

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section

citations: 1

Reference
Jeanpierre S, Arizkane K, Thongjuea S, Grockowiak E, Geistlich K, Barral L, et al. The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. Haematologica. 2021;106:111-122 pubmed publisher

product information

Product Type :

Antibody

Product Name :

BCR-ABL Monoclonal Antibody (7C6)

Catalog # :

MA1-153

Quantity :

100 ug

Price :

US 491.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Human, Mouse

Applications :

Immunocytochemistry: 1:50-1:100, Immunohistochemistry (Paraffin): 1:50-1:500, Immunoprecipitation: 5 ug, Western Blot: 1:500-1:1,000

Species :

Human, Mouse

Clone :

7C6

Isotype :

IgG2a

Storage :

-20 C

Description :

A reciprocal translocation between chromosomes 22 and 9 produces the BCR-ABL fusion oncoprotein, which is found in patients with chronic myelogenous leukemia (CML). Although there are various versions, p210 is the most commonly found BCR-ABL form. The fusion to BCR, results in deregulated/constitutively active tyrosine kinase activity of BCR-ABL which is sufficient of oncogenic transformation of myeloid cells. Inhibition of BCR-ABL oncogenic activity by the ABL-kinase inhibitor STI-571 (also known as gleevec, imatinib) became the first and best example for successful targeted therapy of cancer, and specifically CML. In recent years, several mutations (such as the T351I mutation) were found in CML patients that resulted in STI-571 resistance and the need for additional drug development.

Immunogen :

Bcr686 thyroglobulin conjugate corresponding to human BCR sequence 686-696 (SSINEEITPRRQS)

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:50-1:100, Immunohistochemistry (Paraffin): 1:50-1:500, Immunoprecipitation: 5 ug, Western Blot: 1:500-1:1,000

Aliases :

5133400C09Rik; AI561783; AI853148; ALL; BCR; BCR, RhoGEF and GTPase activating protein; BCR/FGFR1 chimera protein; BCR1; breakpoint cluster region; breakpoint cluster region homolog; breakpoint cluster region protein; CML; D22S11; D22S662; FGFR1/BCR chimera protein; Kiaa3017; mKIAA3017; PHL; Renal carcinoma antigen NY-REN-26